CAS: 50257-40-4; 1-((2,4,6-Triisopropylphenyl)Sulfonyl)-1H-Imidazole

相似化合物

50257-39-1 2232-08-8 86181-71-7

上下游产品

2,4,6-triisopropylphenylsulfonyl chloride 1-(Trimethylsilyl)imidazole 1H-imidazole [(1R,3S,4R,5R,7R)-4-Methyl-3-((E)-styryl)-2,6-dioxa-bicyclo[3.2.1]°Ct-7-yl]-methanol

📜咪唑,2,4,6-三异丙基苯磺酰氯置于三乙胺体系中,用 二氯甲烷 作为反应溶剂,化学反应 2.0H,以93%的收率获得产物1-(2,4,6-三异丙基苯基磺酰)咪唑
参考文献:1-(2,4,6-三异丙基苯基磺酰)咪唑的合成方法
标题:1-(2,4,6-三异丙基苯基磺酰)咪唑的合成方法
摘要:本发明公开了1‑(2,4,6‑三异丙基苯基磺酰)咪唑的合成方法,涉及电解液添加剂技术领域.1‑(2,4,6‑三异丙基苯基磺酰)咪唑的合成方法,其合成步骤如下:步骤一:在0‑50oc的温度下,向装有搅拌器和温度计的反应容器中加入咪唑,三乙胺和有机溶剂a,加入完毕后开启搅拌,得到混合溶液b,向混合溶液b内部滴加含有2,4,6‑三异丙基苯磺酰氯混合溶液c,滴加完毕后,反应2‑6H,得到反应液d.本发明通过合成方法的改进能够有效的提升1‑(2,4,6‑三异丙基苯基磺酰)咪唑的收率,同时能够提高1‑(2,4,6‑三异丙基苯基磺酰)咪唑的纯度,进而能够降低1‑(2,4,6‑三异丙基苯基磺酰)咪唑在生产时和其后续应用所需要的成本.

专利信息

专利号:US-4739073-A
优先权日:1983-11-04
标题:Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, benzyl or M, wherein M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-5354772-A
优先权日:1982-11-22
标 题:Indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl-(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, R7b or M, wherein R7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:CA-3012054-C
优先权日:2016-03-16
标 题 :Microbial synthesis of isoprenoid precursors, isoprenoids and derivatives including prenylated aromatics compounds